Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on Start Printed Page 13682the estimated reporting, recordkeeping, and third-party disclosure burden associated with the Mammography Quality Standards Act requirements.
Submit either electronic or written comments on the collection of information by April 29, 2013.
Submit electronic comments on the collection of information to http://www.regulations.gov. Submit written comments on the collection of information to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document.
Start Further Info
FOR FURTHER INFORMATION CONTACT:
Daniel Gittleson, Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville, MD 20850, 301-796-5156, Daniel.Gittleson@fda.hhs.gov.
End Further Info
Start Supplemental Information
Under the PRA (44 U.S.C. 3501-3520), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. “Collection of information” is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document.
With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.
Mammography Quality Standards Act Requirements—21 CFR Part 900 (OMB Control Number 0910-0309)—Extension
The Mammography Quality Standards Act requires the establishment of a Federal certification and inspection program for mammography facilities; regulations and standards for accreditation and certification bodies for mammography facilities; and standards for mammography equipment, personnel, and practices, including quality assurance. The intent of these regulations is to assure safe, reliable, and accurate mammography on a nationwide level. Under the regulations, as a first step in becoming certified, mammography facilities must become accredited by an FDA-approved accreditation body (AB). This requires undergoing a review of their clinical images and providing the AB with information showing that they meet the equipment, personnel, quality assurance and quality control standards, and have a medical reporting and recordkeeping program, a medical outcomes audit program, and a consumer complaint mechanism. On the basis of this accreditation, facilities are then certified by FDA or an FDA-approved State certification agency and must prominently display their certificate. These actions are taken to ensure safe, accurate, and reliable mammography on a nationwide basis.
The following sections of Title 21 of the Code of Federal Regulations (CFR) are not included in the burden tables because they are considered usual and customary practice and were part of the standard of care prior to the implementation of the regulations. Therefore, they resulted in no additional burden: 21 CFR 900.12(c)(1) and (c)(3) and 21 CFR 900.3(f)(1). Section 900.24(c) was also not included in the burden tables because if a certifying State had its approval withdrawn, FDA would take over certifying authority for the affected facilities. Because FDA already has all the certifying State's electronic records, there wouldn't be an additional reporting burden.
We have rounded numbers in the “Total Hours” column in all three burden tables. (Where the number was a portion of one hour, it has been rounded to 1 hour. All other “Total Hours” have been rounded to the nearest whole number.)
We do not expect any respondents for § 900.3(c) because all four ABs are approved until April 2020.
FDA estimates the burden of this collection of information as follows:
Table 1—Estimated Annual Reporting Burden
|Activity/21 CFR Section/FDA Form No.||Number of respondents||Number of responses per respondent||Total annual responses||Average burden per response||Total hours 1||Total capital costs||Total operating & maintenance costs|
|Notification of intent to become an AB—900.3(b)(1)||0.33||1||0.33||1||1|
|Application for approval as an AB; full 2—900.3(b)(3)||0.33||1||0.33||320||106||$10,000|
|Application for approval as an AB; limited 3—900.3(b)(3)||5||1||5||30||150|
|AB renewal of approval—900.3(c)||0||1||0||15||1|
|AB application deficiencies—900.3(d)(2)||0.1||1||0.1||30||3|
|AB resubmission of denied applications—900.3(d)(5)||0.1||1||0.1||30||3|
|Letter of intent to relinquish accreditation authority—900.3(e)||0.1||1||0.1||1||1|
|Summary report describing all facility assessments—900.4(f)||330||1||330||7||2,310||$77,600|
|AB reporting to FDA; facility 4—900.4(h)||8,654||1||8,654||1||8,654||4,327|
|AB reporting to FDA; AB 5—900.4(h)||5||1||5||10||50|
|AB financial records—900.4(i)(2)||1||1||1||16||16|
|Start Printed Page 13683|
|Former AB new application—900.6(c)(1)||0.1||1||0.1||60||6|
|Reconsideration of accreditation following appeal—900.15(d)(3)(ii)||1||1||1||2||2|
|Application for alternative standard—900.18(c)||2||1||2||2||4|
|Alternative standard amendment—900.18(e)||10||1||10||1||10|
|Certification agency application—900.21(b)||0.33||1||0.33||320||106||$208|
|Certification agency application deficiencies—900.21(c)(2)||0.1||1||0.1||30||3|
|Certification electronic data transmission—900.22(h)||5||200||1000||0.083||83||$30,000|
|Changes to standards—900.22(i)||2||1||2||30||60||$20|
|Certification agency minor deficiencies—900.24(b)||1||1||1||30||30|
|Appeal of adverse action taken by FDA—900.25(a)||0.2||1||0.2||16||3|
|Inspection fee exemption—FDA Form 3422||700||1||700||0.25||175|
|1 Total hours have been rounded.|
|2 One time burden.|
|3 Refers to accreditation bodies applying to accredit specific full-field digital mammography units.|
|4 Refers to the facility component of the burden for this requirement.|
|5 Refers to the AB component of the burden for this requirement.|
Start Printed Page 13684
Table 2—Estimated Annual Recordkeeping Burden
|Activity/21 CFR Section||No. of recordkeepers||No. of records per recordkeeper||Total annual records||Average burden per recordkeeping||Total hours 1||Total capital costs||Total operating and maintenance costs|
|AB transfer of facility records—900.3(f)(1)||0.1||1||0.1||0||1|
|Consumer complaints system; AB—900.4(g)||5||1||5||1||5|
|Documentation of interpreting physician initial requirements—900.12(a)(1)(i)(B)(2)||87||1||87||8||696|
|Documentation of interpreting physician personnel requirements—900.12(a)(4)||8,654||4||34,616||1||34,616|
|Permanent medical record—900.12(c)(4)||8,654||1||8,654||1||8,654||$28,000|
|Procedures for cleaning equipment—900.12(e)(13)||8,654||52||450,008||0.083||37,351|
|Consumer complaints system; facility—900.12(h)(2)||8,654||2||17,308||1||17,308|
|Certification agency conflict of interest—900.22(a)||5||1||5||1||5|
|Processes for suspension and revocation of certificates—900.22(d)||5||1||5||1||5|
|Processes for appeals—900.22(e)||5||1||5||1||5|
|Processes for additional mammography review—900.22(f)||5||1||5||1||5|
|Processes for patient notifications—900.22(g)||3||1||3||1||3||$30|
|Evaluation of certification agency—900.23||5||1||5||20||100|
|1 Total hours have been rounded.|
Table 3—Estimated Annual Third-Party Disclosures 1
|Activity/21 CFR Section||Number of respondents||Number of disclosures per respondent||Total annual disclosures||Average burden per disclosure||Total hours 2||Total operating and maintenance costs|
|Notification of facilities that AB relinquishes its accreditation—900.3(f)(2)||0.1||1||0.1||200||20||$50|
|Clinical images; facility 2—900.4(c), 900.11(b)(1), and 900.11(b)(2)||2,885||1||2,885||1.44||4,154|
|Clinical images; AB 3—900.4(c)||5||1||5||416||2,080||230,773|
|Phantom images; facility 2—900.4(d), 900.11(b)(1), and 900.11(b)(2)||2,885||1||2,885||0.72||2,077|
|Phantom images; AB 3—900.4(d)||5||1||5||208||1,040|
|Annual equipment evaluation and survey; facility 2—900.4(e), 900.11(b)(1), and 900.11(b)(2)||8,654||1||8,654||1||8,654||8,654|
|Annual equipment evaluation and survey; AB 3—900.4(e)||5||1||5||1,730||8,650|
|Provisional mammography facility certificate extension application—900.11(b)(3)||0||1||0||0.5||1|
|Mammography facility certificate reinstatement application—900.11(c)||312||1||312||5||1,560||24,000,000|
|Lay summary of examination—900.12(c)(2)||8,654||5,085||44,005,590||0.083||3,652,464|
|Lay summary of examination; patient refusal 4—900.12(c)(2)||87||1||87||0.5||44|
|Report of unresolved serious complaints—900.12(h)(4)||20||1||20||1||20|
|Information regarding compromised quality; facility 2—900.12(j)(1)||20||1||20||200||4,000||300|
|Information regarding compromised quality; AB 3—900.12(j)(1)||20||1||20||320||6,400||600|
|Patient notification of serious risk—900.12(j)(2)||5||1||5||100||500||19,375|
|Reconsideration of accreditation—900.15(c)||5||1||5||2||10|
|Notification of requirement to correct major deficiencies—900.24(a)||0.4||1||0.4||200||80||68|
|Notification of loss of approval; major deficiencies—900.24(a)(2)||0.15||1||0.15||100||15||25.50|
|Notification of probationary status—900.24(b)(1)||0.3||1||0.3||200||60||51|
|Notification of loss of approval; minor deficiencies—900.24(b)(3)||0.15||1||0.15||100||15||25.50|
|1 There are no capital costs associated with this collection of information.|
|2 Total hours have been rounded.|
End Supplemental Information
Dated: February 22, 2013.
Assistant Commissioner for Policy.
[FR Doc. 2013-04677 Filed 2-27-13; 8:45 am]
BILLING CODE 4160-01-P